Quantcast

Latest CancerVax Stories

2010-12-01 06:00:00

CAMBRIDGE, Mass. and NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) -- a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research -- today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody...

2010-09-28 05:28:00

DALLAS, September 28, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33665-emerging-cancer-vaccines- forecasts-developments-and-pipeline-an.html Search More Than 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Kalorama...

2010-09-20 06:59:00

NESS ZIONA, Israel, September 20, 2010 /PRNewswire-FirstCall/ -- NasVax (TASE: NSVX) announces that it has initiated recruitment and dosing in a Phase 2a clinical trial for oral anti-CD3 (aCD3) monoclonal antibody (MAb) immunotherapy. This study is being conducted at Hadassah Medical Center - Hebrew University in Jerusalem Israel in subjects with nonalcoholic steatohepatitis (NASH), a serious inflammatory disease of the liver, and including those with metabolic syndrome. This Phase 2a...

2010-08-17 07:00:00

SAN DIEGO, Aug. 17 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). Under the SNAP procedures, both initial and follow-on...

2010-08-10 07:00:00

SAN DIEGO, Aug. 10 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the follow-on Phase 2 grant award from the National Cancer Institute under the Small Business Technology Transfer Program (STTR). The grant is in the amount of $1,100,000 over the next two years subject to...

2010-08-09 10:10:00

GAITHERSBURG, Md., Aug. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical...

2010-06-29 07:30:00

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating the potency of new product candidates based on the Company's proprietary BiTE® antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells. Results published in PNAS characterize new BiTE antibodies...

2010-06-15 15:47:07

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research. "Our results provide preclinical evidence for the rational combination of BRAF-targeted therapy and immunotherapy in the treatment of this most dangerous type of skin cancer," said lead researcher Jennifer A....

2010-06-07 14:28:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group. As part of an in-depth review of the history and competitive landscape of what he calls the "cancer vaccine revolution," Dr. Malik concludes that "NWBT has...

2010-06-07 08:00:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors. MT110 is designed to direct a patient's T cells, the immune system's most potent killer cells, against cancer cells that...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.